WANY
ZVRA icon

Wealthspire Advisors (New York)’s Zevra Therapeutics ZVRA Stock Holding History

Wealthspire Advisors (New York)’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-101
Closed -$961 – 2961
2025
Q3 		$961 Buy
+101
New +$1.01K ﹤0.01% 2749

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wealthspire Advisors (New York)'s ZVRA Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Zevra Therapeutics (ZVRA) in Q4 2025, closing a stake of 101 shares — an estimated $961 sold.

Wealthspire Advisors (New York) first reported a position in ZVRA in Q3 2025 and held it in 1 quarter. The position peaked at $961 in Q3 2025. 158 funds tracked by Wall St. Rank hold ZVRA as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Zevra Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 101 Zevra Therapeutics shares in Q4 2025, an estimated $961.
  • Wealthspire Advisors (New York) first reported a position in Zevra Therapeutics in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Zevra Therapeutics position peaked at $961 in Q3 2025.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.